Crescita Therapeutics Inc.
CRRTF
$0.36
$0.01273.66%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.54M | 13.02M | 14.26M | 12.80M | 12.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.54M | 13.02M | 14.26M | 12.80M | 12.43M |
| Cost of Revenue | 6.97M | 6.59M | 7.26M | 5.69M | 5.64M |
| Gross Profit | 7.56M | 6.43M | 7.00M | 7.11M | 6.79M |
| SG&A Expenses | 7.43M | 7.50M | 7.80M | 7.82M | 7.63M |
| Depreciation & Amortization | 990.60K | 957.70K | 997.30K | 1.02M | 1.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.81M | 15.48M | 16.52M | 15.05M | 14.85M |
| Operating Income | -1.28M | -2.46M | -2.27M | -2.25M | -2.42M |
| Income Before Tax | -957.90K | -2.21M | -2.03M | -1.87M | -2.06M |
| Income Tax Expenses | -10.00K | -10.00K | -10.00K | 144.80K | 144.80K |
| Earnings from Continuing Operations | -0.95 | -2.20 | -2.02 | -2.01 | -2.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -947.90K | -2.20M | -2.02M | -2.01M | -2.21M |
| EBIT | -1.28M | -2.46M | -2.27M | -2.25M | -2.42M |
| EBITDA | -380.50K | -1.60M | -1.36M | -1.31M | -1.43M |
| EPS Basic | -0.05 | -0.11 | -0.10 | -0.10 | -0.11 |
| Normalized Basic EPS | -0.03 | -0.07 | -0.06 | -0.06 | -0.06 |
| EPS Diluted | -0.05 | -0.12 | -0.11 | -0.11 | -0.11 |
| Normalized Diluted EPS | -0.03 | -0.07 | -0.06 | -0.06 | -0.06 |
| Average Basic Shares Outstanding | 76.36M | 76.87M | 77.43M | 78.30M | 79.39M |
| Average Diluted Shares Outstanding | 76.46M | 76.87M | 77.43M | 78.30M | 79.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |